Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 3

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 3
---
 of increasing the overall voting
power of Class B Shareholders relative to Class A Shareholders, diluting, and diminishing the influence and control of Class A
Shareholders over our company’s affairs.

Our Class A Ordinary Shares
currently trade on The Nasdaq Capital Market under the symbol “NIVF.” The last reported closing price of our Class A Ordinary
Shares September 15, 2025 was $2.01.

We qualify as a “foreign
private issuer,” as defined in Rule 405 under the U.S. Securities Act of 1933, as amended, or the Securities Act, thus we are eligible
for reduced public company reporting requirements, and are permitted to rely on certain exemptions from Nasdaq corporate governance rules.

NewGenIvf Group Limited (“NewGenIvf,”
“Company,” “our,” “we,” or “us”) is a British Virgin Islands holding company with our
operations conducted through our subsidiaries in the Cayman Islands (our wholly-owned subsidiary, NewGenIvf Limited), British Virgin Islands
(our wholly-owned subsidiary, NewGenDigital Limited) and the United States of America (our wholly-owned subsidiary, Microsort Lab Services
LLC) and in Asia (Hong Kong, Thailand, Kyrgyzstan, and the Kingdom of Cambodia). Under this holding company structure, investors are purchasing
equity interests in NewGenIvf, a British Virgin Islands holding company, and obtaining indirect ownership interests in our Cayman Islands,
British Virgin Islands, United States of America and Asian operating subsidiaries. Substantially all of NewGenIvf’s operations and
assets are based in the United States of America, Thailand, Cambodia and Kyrgyzstan. As a result, its businesses and operations are subject
to the changing economic conditions prevailing from time to time in such countries.

On November 21, 2024, the
Company received a notice from the Staff of Nasdaq notifying the Company that its securities are subject to delisting due to the MVPHS
Deficiency and MLVS Deficiency. The Company requested a hearing to appeal the delisting determination before the Nasdaq Hearings Panel
(the “Panel”) on November 27, 2024. On November 29, 2024, the Company received a formal notice from Nasdaq that the Panel
will consider its appeal at an oral hearing on January 28, 2025 (the “Hearing”). On February 19, 2025, the Company
received written decision from the Panel, which granted